



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/520,883	08/25/2005	Jorg Peters	Le A 36 075	7044
35969	7590	05/11/2010	EXAMINER	
Barbara A. Shimci			LI, RUIXIANG	
Director, Patents & Licensing			ART UNIT	PAPER NUMBER
Bayer HealthCare LLC - Pharmaceuticals			16-46	
555 White Plains Road, Third Floor				
Tarrytown, NY 10591				
			MAIL DATE	DELIVERY MODE
			05/11/2010	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No.	Applicant(s)
	10/520,883	PETERS ET AL.
	Examiner RUIXIANG LI	Art Unit 1646

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If no period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on 28 April 2010.

2a) This action is FINAL. 2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) Claim(s) 1,3-7,10-12,19,21 and 22 is/are pending in the application.

4a) Of the above claim(s) _____ is/are withdrawn from consideration.

5) Claim(s) _____ is/are allowed.

6) Claim(s) 1,3-7,10-12,19,21 and 22 is/are rejected.

7) Claim(s) _____ is/are objected to.

8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) Notice of References Cited (PTO-892)
 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)
 3) Information Disclosure Statement(s) (PTO/SB/06)
Paper No(s)/Mail Date _____

4) Interview Summary (PTO-413)
Paper No(s)/Mail Date _____

5) Notice of Informal Patent Application
 6) Other: _____

DETAILED ACTION

Status of Application, Amendments, and/or Claims

Applicant's amendment filed on 04/28/2010 has been entered. Claim 1 is amended. Claims 21 and 2 are added. Claims 1, 3-7, 10-12, 19, 21, and 22 are pending and under consideration.

Withdrawn Objections and/or Rejections

The rejection of claims 2, 8, 13, and 14 are rejected under 35 U.S.C. 103(a) as being unpatentable over Domingues et al. (Journal of Biotechnology 84:217-230, 2000) in view of Wyllie et al. (U.S. Patent No. 5,932,102, Aug. 3, 1999) is made moot by canceled claim.

The rejection of claim 9 under 35 U.S.C. 103(a) as being unpatentable over Domingues et al. (Journal of Biotechnology 84:217-230, 2000) and Wyllie et al. (U.S. Patent No. 5,932,102, Aug. 3, 1999), and further in view of Apeler et al. (EP 1022337 A2, 07/26/2000) is made moot by canceled claim.

The rejection of claim 20 under 35 U.S.C. 103(a) as being unpatentable over Domingues et al. (Journal of Biotechnology 84:217-230, 2000) and Wyllie et al. (U.S. Patent No. 5,932,102, Aug. 3, 1999), and further in view of US Patent No. 5,739,281 (Apr. 14, 1998) is made moot by canceled claim.

Claim Rejections—35 USC § 112, 1st paragraph

(i). The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

(ii). Claims 1, 3-7, 10-12, 19, 21, and 22 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor, at the time the application was filed, had possession of the claimed invention.

Claim 1 recites "a method for obtaining purified native Interleukin-4 (IL-4) or muteins thereof", which introduces new matter. Claims 3-7, 10-12, 19, 21, and 22 depend from claim 1. There is no support for such a claimed method.

Claim Rejections under 35 USC § 112, 2nd paragraph

(i). The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

(ii). Claims 1, 3-7, 10-12, 19, 21, and 22 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 1 is indefinite because it recites "a method for obtaining purified native Interleukin-4 (IL-4) or muteins thereof". When a protein, such as IL-4, is isolated from its

native environment in a cell, it is an isolated or purified protein, not a purified native protein.

Claim Rejections Under 35 U.S.C. §103 (a)

(i). The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

(ii). Claims 1, 3-6, 10, 11, 19, and 21 are rejected under 35 U.S.C. 103(a) as being unpatentable over Domingues et al. (Journal of Biotechnology 84:217-230, 2000) in view of Wyllie et al. (U.S. Patent No. 5,932,102, Aug. 3, 1999) and Gellman et al. (US Patent No. 5,563,057, October 8, 1996).

Domingues et al. teach a method for purifying interleukin-4 or mutants by recombinant expression comprising (a) expression in inclusion bodies (page 220, right column, the 3rd paragraph), (b) disrupting the cells and separating the inclusion bodies, (c) washing inclusion bodies obtained with 0.1 M Tris-HCl pH8/1 mM EDTA/0.1% zwittergent, (d) solubilizing the inclusion bodies in 8 M GdnHCl, (e) renaturating the expression product and purifying the expression product by cross-flow ultrafiltration against five volumes of buffer (page 220, right column, the 4th paragraph to page 221, the first paragraph of left column).

Domingues et al. fail to teach steps (e) and (f) of claim 1, i.e., purifying the guanidine-denatured IL-4 or muteins thereof using an immobilized metal chelate affinity chromatography (IMAC) system and renaturing the guanidine-denatured IL-4 or muteins thereof in the presence of an artificial chaperone.

Wyllie et al. teach a method for purifying a protein containing histidine residues using immobilized metal affinity chromatography (Abstract). Wyllie et al. teach that human IL-4 has 5 histidine residues and is predicted to have high affinity to the immobilized metal (bottom of column 3). Wyllie et al. also teach purifying human IL-4 from *E. coli* using Zinc-chelating affinity chromatography (columns 5 to 6).

Gellman et al. teach the use of an artificial chaperone, such as β -cyclodextrin for refolding enzymes (see Example 1).

Therefore, it would have been obvious to one having ordinary skill in the art at the time the invention was made to modify the method of Domingues et al. to purify the denatured IL-4 or muteins thereof using an immobilized metal chelate affinity chromatography and to use an artificial chaperone, such as β -cyclodextrin for refolding interleukin-4 or mutants thereof with a reasonable expectation of success. One would have been motivated to do so because (i) an immobilized metal chelate affinity chromatography provides an alternative approach for purifying IL-4 as demonstrated by

Wyllie et al. and (ii) an artificial chaperone, such as β -cyclodextrin, causes the detergents to be sequestered from a protein and detergent complex and allows the protein to achieve the correct folding as demonstrated by Gellman et al. (see, e.g. Example 1).

It is also noted that while the cited references do not teach the specific zwitterionic detergents listed in claim 19, it would have been obvious to one having ordinary skill in the art at the time the invention was made to use a zwitterionic detergent, such as CHAPS or zwittergent series, in a washing buffer with a reasonable expectation of success. One would have been motivated to do so because a zwitterionic detergent, such as CHAPS or zwittergent series, has been widely used for such a purpose.

(iii). Claim 7 is rejected under 35 U.S.C. 103(a) as being unpatentable over Domingues et al. (Journal of Biotechnology 84:217-230, 2000) in view of Wyllie et al. (U.S. Patent No. 5,932,102, Aug. 3, 1999) and Gellman et al. (US Patent No. 5,563,057, October 8, 1996) as applied to claims 1, 3-6, 10, 11, 19, and 21 above, and further in view of Apeler et al. (EP 1022337 A2, 07/26/2000).

Domingues et al., Wyllie et al., and Gellman et al. together teach a method for purifying interleukin-4 or mutants by recombinant expression using an immobilized metal chelate affinity chromatography as applied to claims 1, 3-6, 10, 11, 19, and 21 above.

Domingues et al., Wyllie et al., and Gellman et al. fail to teach a method for purifying an interleukin-4 mutant, Interleukin-4 R121D Y124D.

Apeler et al. teach expression of a human interleukin-4 mutant, Interleukin-4 R121D Y124D (page 2, paragraphs [0002] and [0007]).

Therefore, it would have been obvious to one having ordinary skill in the art at the time the invention was made to apply the method taught by Domingues et al., Wyllie et al., and Gellman et al. to purify interleukin-4 R121D Y124D with a reasonable expectation of success. One would have been motivated to do so because the human interleukin-4 mutants, Interleukin-4 R121D Y124D, comprise 5 histidine residues and would have a high affinity to an immobilized metal as taught by Wyllie et al. (bottom of column 3).

(iv). Claim 12 is rejected under 35 U.S.C. 103(a) as being unpatentable over Domingues et al. (Journal of Biotechnology 84:217-230, 2000) in view of Wyllie et al. (U.S. Patent No. 5,932,102, Aug. 3, 1999) and Gellman et al. (US Patent No. 5,563,057, October 8, 1996) as applied to claims 1, 3-6, 10, 11, 19, and 21 above, and further in view of Bonsch et al. (J. Biol. Chem. 270:8452-8457, 1995).

Domingues et al., Wyllie et al., and Gellman et al. together teach a method for purifying interleukin-4 or mutants by recombinant expression using an immobilized metal chelate affinity chromatography as applied to claims 1, 3-6, 10, 11, 19, and 21 above.

Domingues et al., Wyllie et al., and Gellman et al. fail to teach a method for purifying mIL-4 Q116D and Y119D.

Bonsch et al. teach mIL-4 Q116D and Y119D, the murine homologs of human IL-4 R121D and Y124D (Fig. 8; page 8457, right column).

Therefore, it would have been obvious to one having ordinary skill in the art at the time the invention was made to apply the method taught by Domingues et al., Wyllie et al., and Gellman et al. to purify mIL-4 Q116D and Y119D using an immobilized metal chelate affinity chromatography with a reasonable expectation of success. One would have been motivated to do so because mIL-4 Q116D and Y119D, the murine homologs of human IL-4 R121D and Y124D, comprise histidine residues and would have a high affinity to an immobilized metal as taught by Wyllie et al. (bottom of column 3).

(v). Claim 22 is rejected under 35 U.S.C. 103(a) as being unpatentable over Domingues et al. (Journal of Biotechnology 84:217-230, 2000) in view of Wyllie et al. (U.S. Patent No. 5,932,102, Aug. 3, 1999) and Gellman et al. (US Patent No. 5,563,057, October 8, 1996) as applied to claims 1, 3-6, 10, 11, 19, and 21 above, and further in view of Thøgersen et al. (US Patent No. 5,739,281, Apr. 14, 1998).

Domingues et al., Wyllie et al., and Gellman et al. together teach a method for purifying interleukin-4 or mutants by recombinant expression using an immobilized metal chelate affinity chromatography as applied to claims 1, 3-6, 10, 11, 19, and 21 above.

Domingues et al., Wyllie et al., and Gellman et al. fail to teach renaturing the denatured IL-4 or muteins thereof prior to the step of releasing the IL-4 or muteins thereof from the IMAC system.

Thøgersen et al. teach refolding of numerous proteins, including human and murine β 2-microglobulin (Example 1) and human growth hormone (Example 2) by a cyclic folding procedure on Ni^{2+} activated NTA-agarose matrix (Ni^{2+}NTA -agarose).

Therefore, it would have been obvious to one having ordinary skill in the art at the time the invention was made to modify the method of Domingues et al., Wyllie et al., and Gellman et al. to use matrix-assisted refolding taught by Thøgersen et al. wherein the IL-4 remains bound to the IMAC system with a reasonable expectation of success. One would have been motivated to do so because matrix-assisted refolding provides an efficient and alternative approach for refolding of proteins as demonstrated by Thøgersen et al.

Response to Applicants' argument

Applicants argue that the evidence does not establish that one skilled in the art at the time of the invention would predict that guanidine-denatured IL-4 would bind to IMAC-resins. Applicants argue that the specification discloses that while it was well known from the literature that native interleukin-4 is bound to IMAC, it is surprising that guanidine-denatured IL-4 also binds to IMAC resins.

Applicants' argument has been fully considered, but is not deemed to be persuasive because the teachings of Wyllie et al. are not limited to fully natured, native proteins as applicants have argued. From the teachings of Wyllie et al., one of skill in the art would have understood that as long as the HI of at least one of the histidine residue of a protein was at least 2, the protein would bind to an IMAC column. The affinity between a histidine residue and an immobilized metal depends upon the binding of histidine residue to an immobilized metal. Such a binding exists whether the IL-4 protein is denatured or not. Thus, it would have been obvious to one having ordinary skill in the art at the time the invention was made to modify the method of Domingues et al. to purify the denatured IL-4 or muteins thereof using an immobilized metal chelate affinity chromatography with a reasonable expectation of success.

Conclusion

No claims are allowed.

Advisory Information

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ruixiang Li whose telephone number is (571) 272-0875. The examiner can normally be reached on Monday through Friday from 8:30 am to 5:00 pm. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Nickol, can be reached on (571) 272-0835. The fax number for the organization where this application or proceeding is assigned is (571) 273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, please contact the Electronic Business Center (EBC) at the toll-free phone number 866-217-9197.

/Ruixiang Li/
Primary Examiner, Art Unit 1646

Ruixiang Li, Ph.D.
May 9, 2010